Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Mar 22, 2017 (10 years ago)

Olanzapine Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurities/Degradation Specifications: out of specification results for the related substances test parameter (impurities).

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Olanzapine Tablets, 7.5 mg, packaged in a) 30-count bottles (NDC 62756-553-83), b) 100-count bottles (NDC 62756-553-88), and c) 1000-count bottles (NDC 62756-553-18), Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389, 350 Gujarat, India.

Affected NDCs 62756-0553-18 62756-0553-83 62756-0553-88

Compare with the code on your package — it is the most precise check available.

Drug: Olanzapine

Recalling firm
Sun Pharmaceutical Industries, Inc.
NDC code
62756-553-83
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0700-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Olanzapine recalls

See all
Class III · Low risk

Olanzapine Tablets

Failed Impurities/Degradation Specifications:Organic and unspecified impurities above specification.

Ongoing Impurity / degradation Macleods Pharmaceuticals Limited NDC 33342-068-07 D-0867-2026

Other recalls by Sun Pharmaceutical Industries, Inc.

All 2017 recalls
Class II · Moderate risk

Carbamazepine Tablets

CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing

Ongoing cGMP deviation Sun Pharmaceutical Industries INC NDC 51672-4005-3 D-0770-2026
Class II · Moderate risk

Perampanel CIII Tablets

Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.

Ongoing Labeling / mix-up Sun Pharmaceutical Industries INC NDC 51672-4206-6 D-0628-2026